63 active not recruiting. 63 Phase 2, 12 Phase 1, 11 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 63 | Active not recruiting 63 |
| Phase 1 | 12 | Active not recruiting 12 |
| Phase 3 | 11 | Active not recruiting 11 |
Follow Neurocognitive Disorders: new trials by email Literature Review of Neurocognitive Disorders trials Research Report on Neurocognitive Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD) NPI-001, Placebo - Alzheimer´s Disease | Phase 2 | Active not recruiting | Arctic Therapeutics | 33 | 2025-10-14 | 2026-08-03 |
| Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia Neflamapimod, Placebo - Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | Phase 2 | Active not recruiting | EIP Pharma Inc | 20 | 2025-10-02 | 2026-07-06 |
| Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type 12 cm2 - 2 Active DMTS Patches, 6 cm2 - 1 Active and 1 Placebo DMTS Patches, Placebo - 2 Placebo DMTS Patches - Agitation | Phase 2 | Active not recruiting | Teikoku Pharma USA, Inc. | 150 | 2025-09-16 | 2026-10-27 |
| A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease VHB937, Placebo - Alzheimer's Disease | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 96 | 2025-08-07 | 2026-11-05 |
| Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease SKY-0515, SKY-0515 Placebo - Huntington Disease, Huntingtons Disease | Phase 2 / Phase 3 | Active not recruiting | Skyhawk Therapeutics, Inc. | 120 | 2025-05-27 | 2026-05-01 |
| Multi-session Transcranial Alternating Current Stimulation to Improve Dual-task Standing and Brain Activity in Older Adults With Mild Cognitive Impairment real tACS, sham tACS - Mild Cognitive Impairment (MCI) | Phase 2 | Active not recruiting | High Point University | 20 | 2025-05-13 | 2026-09-16 |
| Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults AGB101, Placebo - Hippocampal Overactivity, Dementia | Phase 2 | Active not recruiting | Johns Hopkins University | 60 | 2025-04-17 | 2026-08-31 |
| Use of a Product Containing the Cannabinoids CBD and THC as a Treatment Strategy for Alzheimer's Disease - Alzheimer's Disease and Cannabis Clinical Trial (DAZACANN) Open-Label Phase Cannabis 50 mg of CBD and 5 mg of THC - Alzheimer Disease (AD) | Phase 1 / Phase 2 | Active not recruiting | Federal University of Latin American Integration | 61 | 2025-04-07 | 2025-08-12 |
| Effect of a Multidomain Intervention Plus Turmeric on the Prevention of Cognitive Decline in People Over 55 Years of Age With Insulin Resistance. Turmeric extract, Control: Placebo. 500mg gelatin in capsules 2 times a day - Cognitive Decline, Subjective Cognitive Impairment | Phase 2 / Phase 3 | Active not recruiting | Instituto Mexicano del Seguro Social | 100 | 2025-02-20 | 2026-03-25 |
| A Phase I Clinical Study of ER2001 Injection for the Treatment of Early Manifest Huntington's Disease. ER2001 intravenous injection, Placebo - Huntington Disease | Phase 1 / Phase 2 | Active not recruiting | ExoRNA Bioscience | 27 | 2025-02-11 | 2026-01-14 |
| Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment IV Ketamine - Depression, Mild Cognitive Impairment | Phase 2 | Active not recruiting | Icahn School of Medicine at Mount Sinai | 15 | 2024-11-01 | 2025-01-29 |
| A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI) Lamivudine 300 MG - Mild Cognitive Impairment | Phase 2 | Active not recruiting | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | 23 | 2024-10-28 | 2025-12-04 |
| A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease E2814, Lecanemab, Placebo - Alzheimer's Disease | Phase 2 | Active not recruiting | Eisai Inc. | 105 | 2024-09-30 | 2026-02-11 |
| Study on Ginkgo Biolba Extract Fifty and Mild Cognitive Impairment Associated With CSVD Ginkgo biloba extract 50 dropping pills, Ginkgo biloba extract Ginkgo biloba extract 50 Drops simulant - Mild Cognitive Impairment | Phase 2 / Phase 3 | Active not recruiting | Beijing Tiantan Hospital | 144 | 2024-09-27 | 2026-10-08 |
| Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD) SPG302, Placebo - Alzheimer Disease | Phase 2 | Active not recruiting | Spinogenix | 24 | 2024-07-29 | 2025-08-17 |
| A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease JNJ-64042056, Placebo - Alzheimer Disease | Phase 2 | Active not recruiting | Janssen Pharmaceutica N.V., Belgium | 55 | 2024-07-22 | 2026-11-03 |
| A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD) RO7269162, Placebo - Alzheimer's Disease | Phase 2 | Active not recruiting | Hoffmann-La Roche | 256 | 2024-05-02 | 2026-11-06 |
| Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease Xanamem, Placebo - Dementia Moderate, Dementia, Mild | Phase 2 / Phase 3 | Active not recruiting | Actinogen Medical | 247 | 2024-04-12 | 2026-10-21 |
| Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA) NACA - Hereditary Cystatin C Amyloid Angiopathy (HCCAA), Hemorrhage Brain | Phase 2 | Active not recruiting | Arctic Therapeutics | 15 | 2024-04-03 | 2026-07-21 |
| A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam) Low Dose Benfotiamine, High Dose Benfotiamine, Placebo - Alzheimer Disease | Phase 2 | Active not recruiting | Weill Medical College of Cornell University | 406 | 2024-03-28 | 2026-09-17 |
Showing 20 of 63. Sign in to see all of them.
Alzheimer Disease (29) · Cognitive Dysfunction (22) · Dementia (15) · Huntington Disease (8) · Neurodegenerative Diseases (5) · Frontotemporal Dementia (4) · Brain Diseases (3) · Delirium (3) · Depression (3) · Nervous System Diseases (3) · Central Nervous System Diseases (2) · Cognition Disorders (2) · Genetic Diseases, Inborn (2) · Inflammation (2)
Mental Disorders (61) · Nervous System Diseases (50) · Central Nervous System Diseases (47) · Brain Diseases (46) · Neurodegenerative Diseases (38) · Dementia (33) · Tauopathies (29) · Cognition Disorders (28) · Pathological Conditions, Signs and Symptoms (15) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10) · Dyskinesias (10) · Basal Ganglia Diseases (9) · Nutritional and Metabolic Diseases (9) · Pathologic Processes (9)
lecanemab (3) · Dasatinib (2) · Haloperidol (2) · Lorazepam (2) · Metformin (2) · Quercetin (2) · Sodium Chloride (2) · 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (1) · Amlodipine (1) · Angiotensin Receptor Antagonists (1) · Calcium Channel Blockers (1) · Chlorpromazine (1) · Cholecalciferol (1) · Deferiprone (1) · Dexamethasone (1)
Hoffmann-La Roche (3) · M.D. Anderson Cancer Center (3) · Washington University School of Medicine (3) · Arctic Therapeutics (2) · Columbia University (2) · Novartis Pharmaceuticals (2) · UniQure Biopharma B.V. (2) · Weill Medical College of Cornell University (2) · ADvantage Therapeutics (1) · AO GENERIUM (1) · Actinogen Medical (1) · Acumen Pharmaceuticals (1) · Akira Sekikawa (1) · Alzamend Neuro, Inc. (1) · Aptinyx (1)
United States (44) · United Kingdom (15) · Spain (14) · Australia (13) · France (11) · Canada (9) · Germany (8) · Italy (7) · Japan (7) · Poland (6) · Brazil (5) · Netherlands (5) · Belgium (4) · South Korea (4) · Sweden (4)
David Hui (2) · Randall J Bateman, MD (2) · Achim Schneeberger, MD (1) · Akira Sekikawa, MD, PhD, PhD (1) · Amy Berger, MD (1) · Amy E Brown, MD (1) · Anelyssa D'Abreu, MD (1) · Anthony Caggiano, MD (1) · Arnold Bakker, Ph.D. (1) · Brew Brew, MBBS,MD,DSC (1) · Carol Manning, PhD (1) · David H. Margolin, MD, PhD (1) · David Hasan, MD (1)
PMID 34366147, PMID 36463457, PMID 38489195, PMID 28975307, PMID 32116309, PMID 32250312, PMID 32479786, PMID 32980252, PMID 33236783, PMID 34687726, PMID 36538409, PMID 37017737, PMID 37203336, PMID 37624739, PMID 38018119, PMID 38055260, PMID 38058356, PMID 38297399, PMID 38745011, PMID 38809849, PMID 39800458, PMID 39974075, PMID 40009460, PMID 40120616, PMID 40226119, PMID 40235521, PMID 40742738, PMID 40838083, PMID 40985290, PMID 41111049, PMID 42179865
2023 (8), R01AG046179 (2), R01AG053267 (2), R56AG053267 (2), U01AG042791 (2), U01AG059798 (2), 2018 (1), R01AG051618 (1), R01AG058691 (1), R01AG061091 (1), R01AG062624 (1), R01AG063826 (1), R01AG065248 (1), R01AG068319 (1), R01AG074971 (1)